期刊
CELL
卷 181, 期 7, 页码 1661-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2020.05.001
关键词
-
资金
- Department of Molecular Biology, Princeton University
- NIH Director's New Innovator Award [1DP2AI124441]
- New Jersey Commission on Cancer Research Pre-doctoral award [DFHS18PPC056]
- National Institute of General Medicine Sciences [T32GM007388]
- National Science Foundation Graduate Research Fellowship [2017249408]
The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据